To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA); Drug: Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)

• Registration Number: NCT00881179
• Lead Sponsor: Sandoz

Brief Summary

To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-05
• Primary Completion: 2002-06
• Study Completion: 2002-06
• Status Verified: 2009-04
• Study First Submitted: 2009-04-13
• Study First Submitted QC: 2009-04-14
• Study First Posted: 2009-04-15
• Last Update Submitted: 2017-03-27
• Last Update Posted: 2017-03-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria

• Positive test results for HIV or hepatitis B or C.
• Treatment for drug or alcohol dependence.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
1	Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)	Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)
2	Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)	Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)

Primary Outcome Measures

Name	Time	Method
Bioequivalence based on AUC and Cmax	9 days